Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M102908200 on June 8, 2001

J. Biol. Chem., Vol. 276, Issue 31, 29051-29058, August 3, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/31/29051    most recent
M102908200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leung, G. K.
Right arrow Articles by Young, S. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leung, G. K.
Right arrow Articles by Young, S. G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Biochemical Studies of Zmpste24-deficient Mice*

Gordon K. LeungDagger §||, Walter K. Schmidt||**, Martin O. BergoDagger §||, Bryant GavinoDagger , Darren H. WongDagger Dagger , Amy Tam**, Matthew N. AshbyDagger , Susan Michaelis**, and Stephen G. YoungDagger §§§

From the Dagger  Gladstone Institute of Cardiovascular Disease, § Cardiovascular Research Institute, and  Department of Medicine, University of California, San Francisco, California 94141-9100, the ** Department of Cell Biology and Anatomy, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and Dagger Dagger  Axys Pharmaceuticals, South San Francisco, California 94080

Received for publication, April 3, 2001, and in revised form, June 4, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Genetic studies in Saccharomyces cerevisiae identified two genes, STE24 and RCE1, involved in cleaving the three carboxyl-terminal amino acids from isoprenylated proteins that terminate with a CAAX sequence motif. Ste24p cleaves the carboxyl-terminal "-AAX" from the yeast mating pheromone a-factor, whereas Rce1p cleaves the -AAX from both a-factor and Ras2p. Ste24p also cleaves the amino terminus of a-factor. The mouse genome contains orthologues for both yeast RCE1 and STE24. We previously demonstrated, with a gene-knockout experiment, that mouse Rce1 is essential for development and that Rce1 is entirely responsible for the carboxyl-terminal proteolytic processing of the mouse Ras proteins. In this study, we cloned mouse Zmpste24, the orthologue for yeast STE24 and showed that it could promote a-factor production when expressed in yeast. Then, to assess the importance of Zmpste24 in development, we generated Zmpste24-deficient mice. Unlike the Rce1 knockout mice, Zmpste24-deficient mice survived development and were fertile. Since no natural substrates for mammalian Zmpste24 have been identified, yeast a-factor was used as a surrogate substrate to investigate the biochemical activities in membranes from the cells and tissues of Zmpste24-deficient mice. We demonstrate that Zmpste24-deficient mouse membranes, like Ste24p-deficient yeast membranes, have diminished CAAX proteolytic activity and lack the ability to cleave the amino terminus of the a-factor precursor. Thus, both enzymatic activities of yeast Ste24p are conserved in mouse Zmpste24, but these enzymatic activities are not essential for mouse development or for fertility.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Proteins that terminate in a carboxyl-terminal CAAX motif1 undergo three sequential enzymatic processing events, farnesylation or geranylgeranylation of the cysteine, endoproteolytic release of the last three amino acid residues of the protein (i.e. removal of the -AAX), and methylation of the new carboxyl terminus of the protein by isoprenylcysteine carboxyl methyltransferase (1, 2). The yeast genes responsible for the farnesylation and methylation steps were identified more than a decade ago (3, 4), but the identification of the genes responsible for the middle processing step, the endoprotease step, remained elusive for years (2). Ultimately, however, Boyartchuk and co-workers (5) applied a novel genetic selection scheme and identified two yeast genes, RCE1 and STE24 (AFC1), involved in the carboxyl-terminal endoproteolytic processing of isoprenylated CAAX proteins. Rce1p is a protease involved in the carboxyl-terminal processing of both a-factor and the yeast Ras protein, Ras2p. Ste24p (Afc1p), a zinc metalloprotease, lacked activity against Ras2p but did process a-factor. Haploid MATa yeast lacking both RCE1 and STE24 (ste24Delta rce1Delta ) grew normally but were unable to produce mature a-factor and therefore were sterile (5). Interestingly, Rce1p and Ste24p exhibited subtle differences in substrate specificities (5-7). Both proteins were capable of cleaving the carboxyl terminus of wild-type a-factor, which terminates in CVIA. However, only Ste24p processed an a-factor mutant terminating in CAMQ, and only Rce1p processed an a-factor mutant terminating in CTLM.2

The identification of Ste24p as a CAAX endoprotease was initially surprising because Ste24p had also been described as a protease that cleaves the amino terminus of the a-factor precursor protein (8), and it seemed improbable that a single protease would recognize and cleave a single protein at two completely different sites. Subsequent studies, however, established that Ste24p does indeed play dual roles in a-factor processing (6, 9). In addition to being a CAAX endoprotease, Ste24p removes the seven amino-terminal amino acids from the a-factor precursor. Ste24 is, however, only the first of two proteases that cleave the amino terminus of a-factor. After the Ste24p-mediated cleavage step, an additional cleavage by Axl1p releases mature biologically active a-factor.

When the two CAAX endoproteases were identified in yeast, apparent orthologues already existed in mammalian cDNA data bases. Tam and co-workers (9) obtained a full-length cDNA for human ZMPSTE24, the orthologue for yeast STE24, and showed that its amino acid sequence was 36% identical to the yeast protein. No a-factor orthologue has been discovered in mammals, and no natural substrates for human ZMPSTE24 have been identified. However, the human enzyme faithfully carried out both the amino-terminal and carboxyl-terminal processing of a surrogate substrate, yeast a-factor, and restored a-factor production in MATa ste24Delta rce1Delta yeast (9, 10).

Our laboratory has sought to define the physiologic importance of the mammalian CAAX endoproteases, as well as the CAAX methyltransferase, isoprenylcysteine carboxyl methyltransferase (ICMT). We cloned and expressed cDNAs for human and mouse Rce1 and showed that the mammalian Rce1 proteins processed the Ras proteins as well as several other CAAX proteins (11, 12). Rce1 knockout mice died during embryonic development (11). However, studies with Rce1-deficient embryos and embryonic fibroblasts showed that Rce1 is essential for Ras processing (11). Like Rce1, ICMT is essential for the processing of mammalian CAAX proteins and also for survival during embryonic development (13).

In the current study, we have turned our attention to cloning mouse Zmpste24 and producing Zmpste24-deficient mice. When we initiated this project, we had several physiologic and biochemical issues in mind. First, we wanted to gauge the physiologic importance of Zmpste24 in mammals. Would Zmpste24 be required for embryonic development, as was the case for Rce1 and ICMT? If Zmpste24-deficient mice survived, would they be fertile? From the biochemical perspective, we wanted to determine whether mouse Zmpste24 would be capable of carrying out the carboxyl-terminal processing of a-factor and, if so, whether the mouse enzyme would manifest the same peculiar specificities as the yeast enzyme (e.g. the ability to cleave an a-factor mutant terminating in CAMQ). We also wanted to determine whether the mouse enzyme would cleave the amino terminus of yeast a-factor and, if so, whether this enzymatic activity would be present in detectable levels in the tissues of wild-type mice. Finally, we wanted to determine if mouse Zmpste24 was the only mammalian enzyme capable of carrying out the amino-terminal processing of a-factor, or whether mammalian cells might contain more than one enzyme with that activity. Our current studies provide insights into each of these issues.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A Mouse Zmpste24 cDNA Clone-- A XREFdb query (14) of GenBankTM sequences with yeast STE24 sequences identified a human expressed sequence tag with sequence similarities (I.M.A.G.E. clone 284572, Research Genetics, Huntsville, AL). Oligonucleotide primers 5'-GAGTTTCAAGCTGATGCATTTGC-3' and 5'-GAGTTTCAAGCTGATGCATTGC-3' derived from the human sequence were used to amplify a 382-base pair (bp) fragment (representing sequences from Zmpste24 exons 9 and 10) from a mouse liver cDNA library. The 5' portion of the mouse Zmpste24 cDNA was generated by 5' rapid amplification of cDNA ends with oligonucleotide 5'-AGTCTTTAGCCTTCCCAAGTTTCTTGGC-3' (corresponding to Zmpste24 amino acids 422-430) and the Marathon-Ready mouse liver cDNA kit (CLONTECH, Palo Alto, CA). Oligonucleotides 5'-ACTCTCCGAGGGACGCGTGT-3' and 5'-CTTAAGAGCATCCAGTCATG-3' were used to amplify a mouse Zmpste24 cDNA. The cDNA was cloned into a TOPO TA cloning vector (Invitrogen, Carlsblad, CA), and both strands were sequenced. Predicted transmembrane domains were determined with the TMHMM transmembrane domain analysis program (genome.cbs.dtu.dk/services/TMHMM-1.0/). Amino acid sequences from different species were aligned with MacVector 6.5.

Expression of Zmpste24 in different mouse tissues was assessed by hybridizing a 32P-labeled Zmpste24 cDNA probe to a mouse Multiple Choice Northern blot (OriGene Technologies, Rockville, MD) and to a mouse multiple-tissue poly(A)+ RNA blot (CLONTECH). Hybridization and washing were performed as described previously (12). The blots were exposed to x-ray film for 72 h at -80 °C.

Yeast Strains and Methods-- JRY5314 MATa his3-11 leu2-3,112 trp1 ura3-1; JRY5315 ste24Delta ::HIS3; JRY5316 rce1Delta ::TRP1; JRY5317 ste24Delta ::HIS3 rce1Delta ::TRP1; JRY5463 MATa mfa1::hisG mfa2::hisG ura3 leu2 his3 trp1 ste24Delta ::HIS3 rce1Delta ::TRP1; and JRY3443 MATalpha trp1 ura1 his3 sst2-4oc were provided by Dr. Jasper Rine (University of California, Berkeley). Each of the JRY strains was isogenic. SM3614 MATa trp1 leu2 ura3 his4 can1 ste24::LEU2 rce1::TRP1 pSM1317 was used as a source of methyltransferase (9, 15). SM1086 MATalpha sst2-1 rme his6 met1 can1 cyh2 was also used for halo assays to score a-factor production (3, 16). SM3103 MATa trp1 leu2 ura3 his4 can1 ste24::LEU2 pSM219 was used to prepare a P1 a-factor intermediate (4, 8, 10). Yeast strains were grown and maintained by standard methods (16, 17).

Yeast Expression Vectors for Endoproteases-- Expression plasmids for mouse Zmpste24 (pMB4), yeast STE24 (pMB5), yeast RCE1 (pMB6), and mouse Rce1 (pMB7) were created in the vector pMB1. To produce pMB1, the yeast shuttle vector Yeplac195 (18) was modified by inserting an ADH2 promoter and a PGK1 transcriptional terminator into the polylinker. The ADH2 promoter (579 bp upstream of the translational start site) was amplified from W303-1a genomic DNA with oligonucleotides 5'-CAGCTATGACCATGATTACGCCAAGCTTCAAAGGGGCAAAACGTAGGGGCAA-3' and 5'-TTGATCTATCGATTTCAATTCAATTCAATTTATCTAGACATTGTGTATTACGATATAGTTAATAG-3'. The PGK1 transcriptional termination sequence (478 bp downstream from the PGK1 translational stop codon) was amplified with oligonucleotides 5'-CTATTAACTATATCGTAATACACAATGTCTAGATAAATTGAATTGAATTGAAATCGATAGATCAA-3' and 5'-CGTTGTAAAACGACGGCCAGTGAATTCATATGTCTCTGAATGCCAAGGATGG-3'. pMB1 was assembled by recombination in yeast (19) by transforming yeast strain W303-1a with the ADH2 and PGK1 PCR products and Yeplac195 that had been linearized with HindIII and EcoRI.

All expression vectors were created by recombinational cloning after co-transformation of XbaI-cleaved pMB1 and PCR-amplified endoprotease open reading frames. A mouse Zmpste24 open reading frame was amplified with oligonucleotides 5'-CTATTAACTATATCGTAATACACAATGGGGATGTGGGCATCGGTGGAC-3' and 5'-TTGATCTATCGATTTCAATTCAATTCAATTTATCAGTCTTGTTTTGCATTTTTCAGAGC-3'. A mutant Zmpste24 cDNA (pMB9) was also constructed; the mutant lacks the sequences from the 104-bp exon 8, which encodes the zinc-binding HEXXH motif (HEXXH: H, histidine; E, glutamate; X, any amino acid). For this mutant, two fragments of the mouse Zmpste24 cDNA (corresponding to amino acids 1-318 and 354-475) were amplified from Marathon Ready mouse liver cDNA (CLONTECH) with oligonucleotides 5'-CTATTAACTATATCGTAATACACAATGGGGATGTGGGCATCGGTGGAC-3', 5'-CTATTAACTATATCGTAATACACAATGGGGATGTGGGCATCGGTGGAC-3', and 5'-TTGATCTATCGATTTCAATTCAATTCAATTTATCAGTCTTGTTTTGCATTTTTCAGAGC-3' and 5'-TTGATCTATCGATTTCAATTCAATTCAATTTATCAGTCTTGTTTTGCATTTTTCAGAGC-3'. To construct pMB5, a yeast STE24 (YJR117W) open reading frame was amplified from W303-1a genomic DNA with oligonucleotides 5'-CAACTATTAACTATATCGTAATACACAATGTTTGATCTTAAGACGATTCTCG-3' and 5'-TTGATCTATCGATTTCAATTCAATTCAATTTATTAGTTTTTCTTCTTTTCACTAACATAG-3'. To construct pMB6, the yeast RCE1 (YMR274C) open reading frame was PCR amplified from W303-1a genomic DNA with oligonucleotides 5'-CAACTATTAACTATATCGTAATACACAATGCTACAATTCTCAACATTTCTAG-3' and 5'-TTGATCTATCGATTTCAATTCAATTCAATTTACTAAAGGGTTATTCTATAACCAGGAGTT-3'. A mouse Rce1 open reading frame was PCR amplified from Marathon Ready mouse liver cDNA (CLONTECH) with oligonucleotides 5'-CAACTATTAACTATATCGTAATACACAATGTCTGTGTTCTCCTGCTTCAGCCTCGCC-3' and 5'-TTGATCTATCGATTTCAATTCAATTCAATTTATCAGGAGCACAGTAGGGTCTCTGAG-3'.

Documenting That Mouse Zmpste24 Processes Yeast a-Factor-- To test the expression vectors (pMB4, pMB5, pMB6, pMB7, pMB8, and pMB9), each was transformed into MATa ste24Delta rce1Delta yeast (JRY5317). The ability of each expression vector to restore a-factor production was assessed with a standard pheromone diffusion (halo) assay (7). The principle underlying the halo assay is that the production of mature a-factor by a MATa yeast strain results in a zone of growth inhibition (halo) on a lawn of MATalpha sst2 cells.

Analyzing the Substrate Specificity of Mammalian Endoproteases with Halo Assays-- The coding regions of human Rce1 and mouse Zmpste24 were amplified by PCR, as described earlier, and cloned into pACA1 (5). Site-directed mutagenesis was used to change the CVIA CAAX box in the a-factor gene (MFA1) to CAMQ or CTLM. The mutant a-factor plasmids were transformed into a MATa ste24Delta rce1Delta mfa1Delta mfa2Delta strain (JRY5463) (6). Yeast strains expressing the a-factor mutants and either human RCE1 or mouse Zmpste24 were spotted onto a lawn MATalpha sst2 cells (JRY3443) and allowed to grow for 2 days at 30 °C. The production of mature a-factor from a mutant a-factor construct was evident from a halo in the lawn of MATalpha sst2 cells.

Analyzing the Substrate Specificity of Mammalian Endoproteases with a Coupled Proteolysis/Methylation Assay-- The ability of yeast and mouse endoproteases to process 15-mer a-factor peptides terminating in CAMQ or CVIA was assessed in a coupled proteolysis/methylation assay (5, 11, 12). A wild-type CVIA a-factor peptide (YIIKGVFWDPA[farnesyl-C]VIA) and a mutant CAMQ a-factor peptide (YIIKGVFWDPA[farnesyl-C]AMQ) were purchased from California Peptide Research (Napa, CA). Membrane fractions were prepared from ste24Delta rce1Delta yeast (JRY5317) that had been transformed with pMB4, pMB5, pMB6, pMB7, or pMB9. Yeast membranes (100 µg) were mixed with 4 nmol of peptide and 10 µM S-adenosyl-L-[methyl-14C]methionine (55 Ci/mol, Amersham Pharmacia Biotech, Piscataway, NJ) and incubated for 120 min at 37 °C. The methylation reaction was stopped by adding 50 µl of 1.0 M NaOH containing 0.1% SDS. The reaction mixture (90 µl) was spotted onto a pleated 2 × 8-cm filter paper wedged in the neck of a 20-ml scintillation vial containing 5 ml of scintillation fluid (ScintiSafe Econo 1, Fisher). The vials were capped and incubated at room temperature for 5 h to allow the [14C]methanol (formed by base-hydrolysis of methyl esters) to diffuse into the scintillation fluid (20-22).

Construction of a Zmpste24 Gene-Targeting Vector-- The screening of a strain 129/Sv bacterial artificial chromosome (BAC) library (Research Genetics) with the 382-bp cDNA fragment resulted in the identification a BAC clone (223 G6) that contained the 3' portion of mouse Zmpste24. A 9.4-kb SpeI fragment containing Zmpste24 exons 7-9 was subcloned into pBSSK (Stratagene, La Jolla, CA). These sequences were used to construct a sequence-replacement gene-targeting vector in pKSLoxPNT (23). pKSLoxPNT contains polylinker cloning sites, a thymidine kinase (tk) gene, and a 3-phosphoglycerate kinase-neomycin resistance (PGK-neo) cassette flanked by loxP sites. The long arm (4.6 kb of intron sequences 5' to exon 8) was amplified from BAC DNA with oligonucleotides 5'-CAAGTGATTCGAGGCTAGCCTGGTCTACG-3' and 5'-GGCCTTGACCCATCTAATCAAACAACCAGAC-3' and the Expand Long Template PCR System (Roche Molecular Biochemicals, Indianapolis, IN). The PCR fragment was cloned into the EcoRI site of pKSLoxPNT. The short arm (2.6 kb of intron sequences 3' to exon 8) was amplified with oligonucleotides 5'-ACGACGGCGGCCGCGAAACTGGCCTGGTGTTCACTATGTAGC-3' and 5'-AGCAGCGCGGCCGCGAGGGCACAACACTGTATGTTACCAGG-3' and cloned into the NotI site. The integrity of the vector was verified by restriction mapping and DNA sequencing. The vector was linearized with XhoI before the electroporation of mouse embryonic stem (ES) cells.

Generation of Zmpste24-deficient Mice-- Mouse ES cells (strain 129/SvJae) (24) were cultured on mitomycin C-treated STO feeder cells in high-glucose Dulbecco's modified Eagle's medium supplemented with 15% ES cell-grade fetal bovine serum, 2 mM L-glutamine, 6 mM HEPES, 100 units/ml penicillin, 100 µg/ml streptomycin, 1 × nonessential amino acids (Hyclone, Logan, UT), 0.14 mM 2-mercaptoethanol (Sigma), and 1000 units/ml leukemia inhibitory factor (Life Technologies, Rockville, MD). G418 (final concentration, 200 µg/ml) was added to the medium 24 h after the electroporation. 1-(2'Deoxy-2'fluoro-beta -D-arabinofuranosyl)-5-iodouracil (final concentration, 0.2 µM) was added to the medium for 4 days, beginning 3 days after the electroporation. Drug-resistant ES cell colonies were picked 10 days after the electroporation, and targeted clones (Zmpste24+/-) were identified by Southern blotting of EcoRI-digested ES cell DNA with a 441-bp 5'-flanking probe (see Fig. 1A). The 5' probe, which was amplified from BAC DNA with oligonucleotides 5'-CCCACAACTGTGGACTTTGATGGATCAGG-3' and 5'-GGTATGCACCACCTTCCCCTGACTACT-3', detects an 8.0-kb EcoRI fragment in wild-type (Zmpste24+/+) cells. Targeted cells (Zmpste24+/-) were identified by the presence of a 5.0-kb fragment in addition to the 8.0-kb fragment. Targeted clones were also screened by digesting genomic DNA with SpeI and then performing a Southern blot with a 388-bp 3'-flanking probe (see Fig. 1A). The 3' probe was amplified from BAC DNA with oligonucleotides 5'-CTAGACTCTTTGGGGTAGTG-3' and 5'-ACGACGGCGGCCGCGGCTTAGTGGGTCCTGGAAGGAACTTTA-3'. The 3' probe detects a 9.4-kb SpeI fragment in Zmpste24+/+ cells; Zmpste24+/- cells contained a 4.3-kb fragment in addition to the 9.4-kb fragment.

Two targeted clones, each with a single neo integration, were used to generate Zmpste24-deficient mice (25). All mice had a mixed genetic background (~50% C57BL/6 and ~50% 129/Sv). The mice were weaned at 21 days of age, housed in a barrier facility with 12-h light/dark cycle, and fed a chow diet containing 4.5% fat (Ralston Purina, St. Louis, MO). All mice described herein were examined at 8-12 weeks of age. Zmpste24-/-, Zmpste24+/-, and Zmpste24+/+ embryonic fibroblasts were prepared from 13.5-day mouse embryos (11).

Production of Chimeric Mice from Zmpste24-/-ES Cells-- Homozygous knockout cells (Zmpste24-/-) were isolated as described by Mortensen et al. (26). Two lines of Zmpste24-/- ES cells were injected into C57BL/6 blastocysts to generate chimeric mice. At 8 weeks of age, the chimeric mice were sacrificed, and genomic DNA from multiple tissues was analyzed with Southern blots with the 5' probe.

Bioassays to Assess Carboxyl-terminal Processing of an a-Factor Peptide by Membranes from Mouse Cells and Tissues-- The ability of Zmpste24-/- membranes to cleave the carboxyl terminus of an a-factor peptide, generating mature a-factor, was assessed with a bioassay.3 Membranes from tissues of Zmpste24+/+ and Zmpste24-/- mice and from Zmpste24+/+ and Zmpste24-/- cells were mechanically disrupted by sonication (Branson sonifier, 10 cycles, output = 5, duty cycle = 50%) in an ice-cold hypotonic lysis buffer (10 mM Tris-HCl, 1 mM MgCl2, 1 µM dithiothreitol, pH 7.4 containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin, and 3 µg/ml leupeptin, chymostatin, and pepstatin). The samples were then homogenized on ice with a Dounce homogenizer, resuspended in 0.15 M NaCl, and then subjected to centrifugation at 4 °C for 3000 × g for 10 min. The pellet was discarded and the supernatant fluid was spun at 100,000 × g for 30 min at 4 °C. The supernatant fluid was discarded and the pellet, representing the membrane fraction, was resuspended in ice-cold buffer (50 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 1 mM EDTA, 100 mM NaCl, and protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin, and 3 µg/ml leupeptin, chymostatin, and pepstatin)) at concentrations of 3-14 mg/ml and then frozen at -80 °C. A 100 µM solution of the CAMQ peptide was prepared in methanol. Membranes from ste24Delta rce1Delta yeast that expressed STE14 from a 2-µm plasmid (SM3614/pSM1317) were prepared as a source of the prenylprotein methyltransferase (15). Each carboxyl-terminal processing reaction contained the a-factor peptide (0.75 µM), membranes from mouse tissues (75 µg/ml), ste24Delta rce1Delta /Ste14p yeast membranes (0.1 mg/ml) in a buffer containing 75 mM HEPES, 75 mM NaCl, 15 mM EDTA, pH 7.5, and 20 µM S-adenosyl-L-methionine. The reactions were assembled in 96-well polystyrene plates in a total volume of 25 µl. After a 2-h incubation at 30 °C, the reactions were terminated by adding copper acetate (final concentration, 2 mM). The production of mature a-factor was detected by plating dilutions of the reaction mixture on a lawn of MATalpha sst2 cells (SM1086) and allowing the cells to grow for 2 days at 30 °C (27, 28).3 Mature a-factor results in a zone of growth inhibition in the lawn of cells.

Assessing the Ability of Mouse Membranes to Carry Out the Amino-terminal Processing of P1 a-Factor-- Yeast membranes containing radiolabeled P1 a-factor were prepared as previously described (10). P1 a-factor is fully COOH-terminal modified (i.e. isoprenylated, cleaved, and carboxyl methylated) (29). In a wild-type strain, COOH-terminal processing of a-factor occurs first and is followed by NH2-terminal processing (29). Isoprenylation is required (29) for the production of P1 a-factor, but blocking either methylation (30) or CAAX processing4 does not impede NH2-terminal processing. Briefly, a yeast strain lacking STE24 but expressing MFA1 from a high-copy plasmid (SM3103/pSM219) was radiolabeled with [35S]cysteine, and membranes containing P1 a-factor were isolated (10). Proteolysis reactions (typically 50 µl) were assembled on ice in polystyrene 96-well plates. Each reaction contained the metabolically labeled yeast membranes (0.5 mg/ml) and membranes (0.5 mg/ml) from Zmpste24+/+ or Zmpste24-/- cells or tissues in a buffer containing 100 mM HEPES and 100 mM NaCl, pH 7.5. Some of the reaction mixtures contained 2 mM 1,10-phenanthroline, a zinc chelator. After a 2-h incubation at 30 °C, reactions were terminated by adding 1% SDS and heating the samples to 100 °C for 3 min. The a-factor intermediates were immunoprecipitated with an a-factor-specific antiserum. Each immunoprecipitate was then size-fractionated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed with a PhosphorImager (10, 29).

Assessing the Accumulation of "Methylatable" Substrates in Rce1-, ICMT-, and Zmpste24-deficient Fibroblasts-- Whole cell extracts (150 µg) from primary fibroblasts (Zmpste24+/+, Zmpste24-/-, ICMT+/+, ICMT-/-, Rce1+/+, and Rce1-/-) (11, 13) were incubated with 10 µM S-adenosyl-L-[methyl-14C]methionine (55 Ci/mol, Amersham Pharmacia Biotech), Sf9 cells expressing high levels of Ste14p (100 µg), yeast membranes expressing high levels of mouse Rce1 (100 µg), and yeast membranes containing high levels of mouse Zmpste24 (100 µg). The reaction was incubated for 2 h at 37 °C, and the levels of methylatable substrates in the wild-type and knockout cell extracts were compared with the base hydrolysis/methanol diffusion assay.

We also incubated whole cell extracts from Rce1+/+ and Rce1-/- fibroblasts in the presence of yeast membranes containing high levels of mouse Rce1 or yeast membranes containing high levels of mouse Zmpste24. All incubations contained 10 µM S-adenosyl-L-[methyl-14C]methionine and Escherichia coli membranes containing high levels of yeast Ste14p (4). The reactions were incubated for 2 h at 37 °C, and the levels of methylatable substrates in the cell extracts were compared with the base hydrolysis/methanol diffusion assay. All incubations were performed in duplicate.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A Mouse Zmpste24 cDNA-- DNA sequencing of a mouse Zmpste24 cDNA revealed that the mouse enzyme, like the human enzyme, contains 475 amino acids (Fig. 1). The mouse and human amino acid sequences were 93% identical. Both the mouse and human sequences were 36% identical to the S. cerevisiae Ste24p sequence, with the highest levels of similarity within the last third of the molecule. Mouse Zmpste24, like the human and yeast enzymes, has a HEXXH motif (residues 335-339) that is characteristic of zinc metalloproteinases (5, 8, 9) and multiple membrane-spanning domains (Fig. 1). Mouse Zmpste24 is expressed in multiple tissues, with the highest levels of expression in the liver and kidney (Fig. 2).


View larger version (78K):
[in this window]
[in a new window]
 
Fig. 1.   The mouse Zmpste24 amino acid sequence, aligned with the human and yeast sequences. A conserved HEXXH zinc-binding motif is present in each of the three sequences (residues 335-339 of the mouse and human sequence). The mouse sequence is predicted to contain multiple transmembrane domains (residues 19-37, 80-102, 121-143, 171-189, 198-216, 349-367, and 386-408). The yeast and human sequences also are predicted to contain multiple transmembrane domains (2). GenBankTM for mouse Zmpste24 cDNA sequence: AY029194.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 2.   Northern blot showing Zmpste24 expression in multiple mouse tissues. A 32P-labeled Zmpste24 cDNA probe was hybridized to a mouse Multiple Choice Northern blot (OriGene). Loading of samples was normalized to beta -actin. The blot was exposed to x-ray film for 72 h at -80 °C. A similar pattern was observed with a multiple tissue poly(A)+ RNA blot from CLONTECH (not shown).

Functional Studies of Mouse Zmpste24 in Yeast-- To assess the functional integrity of mouse Zmpste24, a yeast plasmid encoding the Zmpste24 cDNA was transformed into ste24Delta rce1Delta yeast. The transformed cells were tested for the ability to produce a-factor with an established bioassay that utilizes a lawn of MATalpha sst2 cells. Nontransformed ste24Delta rce1Delta yeast do not produce a zone of growth inhibition (halo) on the lawn of MATalpha sst2 cells since they cannot form mature a-factor. The plasmid encoding mouse Zmpste24 restored a-factor production, as judged by the halo surrounding the colony (Fig. 3A). Mouse Rce1 also restored a-factor production (Fig. 3A). In anticipation of performing a gene-targeting experiment in mice, we sought to establish that the removal of the 104-bp exon 8 of Zmpste24 (encoding amino acids 318-354, containing the HEXXH motif) would inactivate the gene product. We therefore transformed the ste24Delta rce1Delta yeast with a mutant mouse Zmpste24 cDNA lacking exon 8 sequences. The mutant cDNA did not restore a-factor production (Fig. 3A).


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 3.   Yeast halo assays demonstrating that mouse Zmpste24 complements the defect in a-factor production in ste24Delta rce1Delta yeast. A, halo assay demonstrating that the expression of yeast RCE1 (from plasmid pMB6), mouse Rce1 (pMB7), yeast STE24 (pMB5), and mouse Zmpste24 (pMB4) restores the production of a-factor in ste24Delta rce1Delta yeast (JRY5317 ste24Delta ::HIS3 rce1Delta ::TRP1). A mutant mouse Zmpste24 construct lacking exon 8 sequences (which encode the HEXXH motif) did not restore a-factor production. B, halo assay demonstrating that yeast expressing mouse Zmpste24 process a mutant a-factor terminating in CAMQ (halo marked by arrows) but not a mutant terminating in CTLM (absent halo). Yeast expressing mouse Rce1 process a mutant a-factor terminating in CTLM (halo marked by arrows) but not a mutant terminating in CAMQ (absent halo). The halos in Panel B are smaller than in Panel A because detergents were not included in the agar in Panel B. C, coupled endoproteolysis/methylation assay demonstrating that the CAMQ a-factor peptide is cleaved and methylated by membranes from ste24Delta rce1Delta yeast (JRY5317) that overexpress mouse Zmpste24 or yeast STE24 but not by membranes that overexpress yeast RCE1, mouse Rce1, or the mutant mouse Zmpste24. D, coupled endoproteolysis/methylation assay demonstrating that the CVIA a-factor peptide is cleaved and methylated by membranes from ste24Delta rce1Delta yeast that express mouse Zmpste24, yeast STE24, mouse Rce1, and yeast RCE1, but not by the mutant mouse Zmpste24.

Boyartchuk and co-workers (6) demonstrated that yeast Ste24p and Rce1p have distinct specificities for a-factor precursors with different CAAX sequences. Both yeast Ste24p and yeast Rce1p processed the wild-type a-factor precursor, which terminates in CVIA (5, 6). Ste24p was uniquely capable of processing mutant a-factor precursor molecules terminating in CAMQ, while Rce1p was uniquely capable of cleaving a mutant a-factor terminating in CTLM. Interestingly, we found that the mammalian enzymes exhibited the same specificities. Both mouse Rce1 and mouse Zmpste24 were capable of processing the wild-type a-factor terminating in CVIA (Fig. 3A). However, only RCE1 processed a mutant a-factor terminating in CTLM, and only Zmpste24 processed a mutant a-factor terminating in CAMQ (Fig. 3B).

The fact that both yeast Ste24p and mouse Zmpste24 can cleave a CAMQ a-factor was confirmed with coupled endoproteolysis/methylation assays (Fig. 3C). Membranes from ste24Delta rce1Delta yeast that overexpressed yeast STE24 or mouse Zmpste24 cleaved and methylated a CAMQ a-factor peptide. Yeast membranes overexpressing the mutant mouse Zmpste24 (lacking the HEXXH motif) did not methylate the peptide, nor did yeast membranes that overexpressed yeast Rce1p or mouse Rce1. In contrast, membranes from yeast expressing mouse Zmpste24, yeast STE24, mouse Rce1, and yeast RCE1 cleaved and then methylated the wild-type CVIA a-factor peptide (Fig. 3D).

Zmpste24 Knockout Mice-- A gene-targeting vector designed to replace exon 8 of Zmpste24 with a neo was used to inactivate mouse Zmpste24 (Fig. 4A). Approximately 1 in 30 drug-resistant clones was targeted (Fig. 4B). Two ES cell lines were used to generate Zmpste24+/- mice, which were bred to generate Zmpste24-/- mice (Fig. 4C). Zmpste24-/- mice (produced from both targeted ES cell clones) were born at the expected mendelian frequency and were viable and fertile. To assess the relative capacities of wild-type cells and Zmpste24-/- cells to contribute to the formation of different mouse tissues, chimeric mice were generated with Zmpste24-/- ES cells (Fig. 4D). A total of 12 high-percentage (>90%) chimeric mice were obtained. As judged by Southern blot analysis, the Zmpste24-deficient ES cells contributed robustly to the formation of each tissue that was analyzed (heart, lung, liver, spleen, kidney, adipose, brain, intestine, skin, testes, and skeletal muscle) (not shown).


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 4.   Inactivating the mouse Zmpste24 gene. A, sequence-replacement gene-targeting vector designed to replace Zmpste24 exon 8 with a neo. Mouse exons were numbered according to corresponding exons in the human gene sequence (BAC clone RP1-39G22, GenBankTM AL05034). B, Southern blots identifying gene-targeting events in mouse ES cells. C, Southern blot identification of 4-week-old Zmpste24+/+, Zmpste24+/-, and Zmpste24-/- mice with the 5'-flanking probe. D, Southern blot demonstrating the production of Zmpste24-/- ES cells. The Zmpste24-/- cells were generated by growing Zmpste24+/- in high concentrations of G418, as described by Mortensen et al. (26). The genomic DNA was digested with EcoRI, and the blot was hybridized with the 5'-flanking probe.

Assessing Zmpste24 Enzymatic Activity Levels-- We next sought to determine if the targeted mutation in Zmpste24-/- mice was associated with detectable changes in enzymatic activity levels. Since no natural substrates for mammalian Zmpste24 have been described, we tested the possibility that the membranes from Zmpste24-/- cells and tissues would be deficient in their capacity to process a surrogate substrate, yeast a-factor. In the first series of experiments, we incubated Zmpste24-/- and Zmpste24+/+ membranes with the CAMQ a-factor peptide in the presence of S-adenosyl-L-[methyl-14C]methionine, and then assessed base-labile methylation of the peptide. Similar levels of methylation were observed with both Zmpste24-/- and Zmpste24+/+ membranes (Zmpste24+/+, 0.82 ± 0.02 pmol/mg/min; Zmpste24-/- 0.78 ± 0.02 pmol/mg/min), and the methylation was sensitive to 1,10-phenanthroline (data not shown). This result was clearly different from what we observed with the coupled endoprotease/methylation assays involving yeast membranes; Zmpste24-containing yeast membranes processed the CAMQ a-factor peptide significantly more than membranes lacking Zmpste24 (see Fig. 3C).

We suspected that the failure to find differences in methylation of the CAMQ a-factor peptide by Zmpste24-/- and Zmpste24+/+ membranes was due to the presence of a membrane-bound, phenanthroline-sensitive exoprotease in the mouse membranes, which would be expected to generate farnesylcysteines or short farnesylcysteine-containing peptides. The latter substances would be readily methylated and would increase the background in the experiment, making it impossible to detect potential differences between the ability of Zmpste24-/- and Zmpste24+/+ membranes to carry out the carboxyl-terminal endoproteolytic processing of a-factor. To circumvent this problem, we decided to perform a more specific assay, a yeast bioassay for fully processed mature a-factor. In this assay, we tested whether membranes from Zmpste24-deficient cells and tissues would be defective in producing mature a-factor from the 15-mer CAMQ a-factor peptide (i.e. defective in cleaving the -AMQ from the peptide, making it a substrate for carboxyl methylation). To address this issue, the CAMQ a-factor peptide was mixed with mouse liver membranes for 2 h, and the production of a-factor was assessed by assessing the ability of mature a-factor to inhibit the growth of MATalpha sst2 yeast. Notably, membranes from livers of Zmpste24-/- mice were 4-8 times less efficient in producing mature a-factor (Fig. 5A). Similar results were observed in other tissues in an independent experiment (Fig. 5B).


View larger version (64K):
[in this window]
[in a new window]
 
Fig. 5.   Reduced carboxyl-terminal processing of a CAMQ a-factor peptide by membranes prepared from livers of Zmpste24-/- mice. A, a CAMQ a-factor peptide was mixed with Zmpste24-/- or Zmpste24+/+ liver membranes (75 µg/ml) and incubated for 2 h at 30 °C. Incubations were performed in the presence and absence of 1,10-phenanthroline. Serial dilutions of the samples were plated on a lawn of MATalpha sst2 yeast cells (SM1086); the production of mature a-factor was judged by inhibition of yeast growth. There was some residual activity in Zmpste24-/- membranes, which could be largely blocked with 1,10-phenanthroline. The residual activity was probably not due to Rce1 because Rce1 activity is not affected significantly by 1,10-phenanthroline (33) and because Rce1 cannot process a CAMQ a-factor peptide. B, independent experiment testing the capacity of membranes from different Zmpste24-/- or Zmpste24+/+ tissues to generate mature a-factor from the same CAMQ a-factor.

We also examined the possibility that membranes from Zmpste24-/- cells and tissues would be deficient in their ability to cleave the amino terminus of an a-factor intermediate. In yeast, both in vivo and in vitro, Ste24p cleaves the seven amino-terminal amino acids from P1 (farnesylated a-factor precursor), generating a shorter intermediate, P2, which can be resolved from P1 by SDS-PAGE (9, 10, 29). We produced a metabolically labeled P1 intermediate in ste24Delta yeast, then tested the ability of Zmpste24-/- and Zmpste24+/+ membranes to cleave the amino terminus from P1, converting it to P2 (Fig. 6). Membranes from Zmpste24+/+ ES cells and fibroblasts converted P1 to P2, and this activity was blocked by 1,10-phenanthroline (Fig. 6A). Membranes from Zmpste24-/- ES cells and fibroblasts lacked this activity (Fig. 6A). Similarly, membranes from the liver, heart, and skeletal muscle of Zmpste24+/+ mice converted P1 to P2, whereas membranes from Zmpste24-/- mice did not (Fig. 6B).


View larger version (61K):
[in this window]
[in a new window]
 
Fig. 6.   Reduced ability of membranes from Zmpste24-/- cells and tissues to carry out the amino-terminal processing of a-factor. An 35S-labeled P1 a-factor intermediate was prepared from a yeast strain that lacked STE24 and expressed MFA1 from a high-copy plasmid. Proteolysis reactions were performed by incubating the radiolabeled P1 with mouse membranes for 2 h at 30 °C in the absence or presence of 1,10-phenanthroline. The a-factor intermediates were then immunoprecipitated with an a-factor-specific antiserum and size-fractionated by SDS-PAGE. Dried gels were analyzed by autoradiography and with a PhosphorImager. The amino-terminal processing reaction cleaves seven amino acids from the amino terminus of P1, yielding the shorter intermediate P2 (9, 29). A, ability of membranes from ES cells and fibroblasts to cleave the P1 a-factor intermediate. B, ability of membranes from Zmpste24-deficient mouse tissues to cleave the P1 a-factor intermediate.

Testing for the Accumulation of Substrates in Rce1-/- and Zmpste24-/- Cells-- Although no natural Zmpste24 CAAX protein substrates have been identified, the high degree of sequence conservation in the enzyme suggests that natural substrates must exist. We hypothesized that significant amounts of CAAX protein substrates might accumulate in both Rce1-deficient cells and Zmpste24-deficient cells. To test that possibility, whole cell extracts from primary fibroblasts (Zmpste24+/+, Zmpste24-/-, Rce1+/+, and Rce1-/-) were incubated with S-adenosyl-L-[methyl-14C]methionine and membranes containing high levels of Ste14p, mouse Rce1, and mouse Zmpste24. As a control, we examined the accumulation of protein substrates in whole cell extracts from ICMT+/+ and ICMT-/- fibroblasts (13). The accumulation of methylatable substrates in each extract was gauged with a base hydrolysis/methanol diffusion assay. As expected, methylatable substrates accumulated in ICMT-/- cells (Fig. 7A). Substrates also accumulated in Rce1-/- cells (Fig. 7A). However, no such accumulation was detectable in Zmpste24-/- cells (Fig. 7A). Similarly, no accumulation of methylatable substrates was detected in extracts of Zmpste24-/- livers, kidneys, or hearts (not shown).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 7.   Absence of a detectable accumulation of "methylatable" substrates in Zmpste24-/- cells. A, methylation of whole cell extracts from primary fibroblasts derived from Zmpste24+/+, Zmpste24-/-, ICMT+/+, ICMT-/-, Rce1+/+, and Rce1-/- embryos. The cell extracts were incubated with S-adenosyl-L-[methyl-14C]methionine, membranes containing high levels of Ste14p, yeast membranes containing high levels of mouse Rce1, and yeast membranes containing high levels of mouse Zmpste24. The relative level of methylatable substrates in wild-type and knockout cells was assessed with a base hydrolysis/methanol diffusion assay. For the Zmpste24+/+ and Zmpste24-/- cells, we observed identical results when membranes expressing Rce1 were left out of the reaction mixture. B, methylation of whole cell extracts from Rce1+/+ and Rce1-/- fibroblasts in the presence of yeast membranes containing high levels of mouse Rce1 or membranes containing high levels of mouse Zmpste24. In these experiments, we demonstrated that the yeast membranes contained active Zmpste24 by showing that they promoted the processing and methylation of the 15-mer CAMQ a-factor substrate, as shown in Fig. 3D.

In a separate experiment, we asked whether Zmpste24 would be capable of processing some or all of the substrates that accumulate in Rce1-deficient cells. Whole cell extracts from Rce1+/+ and Rce1-/- fibroblasts were incubated with Ste14p, S-adenosyl-L-[methyl-14C]methionine, and either mouse Rce1 or mouse Zmpste24. Again, we noted increased methylation when Rce1 was added to extracts from Rce1-deficient cells, reflecting the accumulation of Rce1 substrates in those cells (Fig. 7B). No such increase was observed when Zmpste24 was added to the Rce1-deficient cell extracts (Fig. 7B), indicating that Zmpste24 has little ability to process Rce1 substrates.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have sought to define the physiologic importance of the two endoproteases and the methyltransferase involved in the "post-isoprenylation" processing of proteins containing a CAAX motif (2). We have shown that ICMT and Rce1 are essential for the processing of the Ras proteins and that both are required for embryonic development. The involvement of Rce1 and ICMT in Ras protein processing was not particularly surprising, given that the corresponding yeast genes, RCE1 and STE14, had already been shown to be involved in the processing of yeast Ras2p (4, 5, 31, 32). The fact that knockouts of the two mouse genes yielded lethal developmental phenotypes was also not too surprising given that both are involved in the processing of dozens of isoprenylated proteins. In the current studies, we focused on mouse Zmpste24, the "other" CAAX endoprotease and arguably the most mysterious and intriguing of the three post-isoprenylation protein-processing enzymes.

In yeast, the only known substrate for Ste24p is the mating pheromone a-factor (2, 5, 6, 8-10, 29). Although no a-factor orthologue has yet been identified in mammals, zinc metalloproteases similar to Ste24p can be readily identified in many species throughout the plant and animal kingdoms (2, 9). Interestingly, the level of amino acid sequence identity is higher for yeast Ste24p and mouse Zmpste24 than for yeast Rce1p/mouse Rce1 or for yeast Ste14p and mouse ICMT (2). The high level of sequence similarity initially led us to suspect that Zmpste24 might also encode a key housekeeping protein required for mouse survival. This suspicion was not borne out. Zmpste24-deficient mice developed normally and were fertile. The absence of a lethal phenotype cannot be attributed to a leaky phenotype or a poorly designed knockout experiment. Our gene-targeting vector eliminated the critical HEXXH zinc-binding domain and introduced a frameshift, and we had proven with yeast expression studies, even before embarking on the mouse experiments, that the mutation inactivated the enzyme.

In assessing the biochemical phenotype associated with mouse Zmpste24 deficiency, we used yeast a-factor as a surrogate substrate, since no natural mammalian substrates for Zmpste24 have been identified. Nonetheless, our biochemical studies uncovered new and intriguing findings. First, we found that an enzymatic activity capable of cleaving the amino terminus of a-factor is expressed at readily detectable levels in wild-type mouse ES cells and in multiple tissues of wild-type mice. This enzymatic activity was absent in the setting of Zmpste24 deficiency. Thus, Zmpste24 was the only mammalian enzyme capable of processing the amino terminus of a-factor in vitro; no redundant "Ste24p/Zmpste24-like" amino-terminal cleavage activities were detected. We also demonstrated that Zmpste24-deficient cells are deficient in a specific CAAX endoprotease activity, the ability to cleave the -AAX from a CAMQ a-factor peptide. The use of a CAMQ a-factor peptide was essential for these experiments because it cannot be cleaved by Rce1 (5, 6).

One possible conclusion from the phenotype of the Zmpste24-/- mice is that there are simply no essential Zmpste24 substrates. Alternatively, developmentally essential Zmpste24 substrates may exist but are processed, at least to a degree, by other proteases. In this regard, it is worthwhile pointing out that STE24-deficient yeast are not completely deficient in their ability to produce mature a-factor (2, 5, 6, 9). Some mature a-factor is produced because the carboxyl terminus of a-factor precursor can be cleaved by Rce1p and because the Axl1p-mediated amino-terminal cleavage step proceeds, albeit inefficiently, in the absence of Ste24p. Thus, it is quite conceivable that the viability of Zmpste24-/- mice results from processing of Zmpste24 substrates by other enzymes.

The only known Ste24p substrate in yeast, a-factor, is methylated after the proteolytic release of the carboxyl-terminal tripeptide (4). If unique Zmpste24 CAAX protein substrates were to exist in mammalian cells (i.e. substrates not cleaved by Rce1), we predicted that we would be able to document an accumulation of methylatable substrates in Zmpste24-deficient cells. This prediction was not upheld. No accumulation of methylatable substrates was detected either in Zmpste24-/- ES cells or in a variety of Zmpste24-/- tissues. In contrast, an accumulation of methylatable substrates was easily detectable in both Rce1-deficient cells and ICMT-deficient cells. Recombinant Zmpste24 could not cleave the accumulated substrates in Rce1 knockout cells. How should these studies be interpreted? One could properly conclude that these studies show that a greater number of methylatable protein substrates accumulate in the setting of Rce1 or ICMT deficiency than in Zmpste24 deficiency. One could also conclude that Zmpste24 cannot process the uncleaved substrates in Rce1-deficient cells. However, we would be reluctant to conclude that mammalian cells have no unique Zmpste24 CAAX protein substrates or that all Zmpste24 substrates are cleaved by other enzymes (e.g. Rce1). Unique Zmpste24 substrates may accumulate in Zmpste24 deficiency but at concentrations too low to yield levels of carboxyl methylation above background.

The conservation in the enzymatic specificities for yeast Ste24p and mouse Zmpste24 is remarkable. Mouse Zmpste24 as well as the human enzyme faithfully cleave the amino terminus of yeast a-factor. Moreover, both mouse Zmpste24 and yeast Ste24p share the property of being able to cleave the carboxyl terminus of a wild-type a-factor and a CAMQ a-factor mutant, but not a CTLM a-factor mutant. The striking conservation of Ste24p/Zmpste24 specificities makes it tempting to speculate that an a-factor orthologue is lurking in the mammalian genome. We have not yet identified such a protein, but recognizing an open reading frame as short as 36 amino acids (the length of the a-factor precursor) could be quite challenging. This challenge is compounded when one considers the fact that a-factor-like CAAX proteins from diverse organisms (e.g. Saccharomyces cerevisiae, Schizosaccharomyces pombe, Ustilago maydis, Ustilago hordei, Filobasidiella neoformans) exhibit only limited sequence similarities.

    ACKNOWLEDGEMENTS

We thank J. Rine for sharing yeast strains; S. Clarke for E. coli membranes containing high levels of yeast Ste14p; and P. Casey, S. Ordway, and G. Howard for criticisms of the manuscript.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants HL41633 and AG15451 (to S. G. Y.) and GM41223 (to S. M.), a Howard Hughes Medical Institute Postdoctoral Fellowship for Physicians (to G. K. L.), and grant awards from the University of California Tobacco-related Disease Research Program (to M. O. B. and S. G. Y.).

|| Contributed equally to the results of this work.

§§ To whom reprint requests should be addressed: Gladstone Institute of Cardiovascular Disease, P. O. Box 419100, San Francisco, CA 94141-9100. Tel.: 415-695-3774; Fax: 415-285-5632; E-mail: syoung@ gladstone.ucsf.edu.

Published, JBC Papers in Press, June 8, 2001, DOI 10.1074/jbc.M102908200

2 CAMQ is the CAAX sequence in the alpha -subunit of rabbit muscle phosphorylase kinase; CTLM is the CAAX sequence in yeast Ste18p.

3 A. Tam, W. K. Schmidt, and S. Michaelis, manuscript in preparation.

4 W. K. Schmidt and S. Michaelis, unpublished data.

    ABBREVIATIONS

The abbreviations used are: CAAX motif, carboxyl-terminal CAAX motif is a cysteine (C), a pair of aliphatic amino acids (A), and then a final amino acid residue (X); bp, base pair; PCR, polymerase chain reaction; BAC, bacterial artificial chromosome; ES, embryonic stem; kb, kilobase pair(s); PAGE, polyacrylamide gel electrophoresis.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Casey, P. J., and Seabra, M. C. (1996) J. Biol. Chem. 271, 5289-5292
2. Young, S. G., Ambroziak, P., Kim, E., and Clarke, S. (2000) in The Enzymes (Tamanoi, F. , and Sigman, D. S., eds), Vol. 21 , pp. 155-213, Academic Press, San Diego
3. Powers, S., Michaelis, S., Broek, D., Anna-A, S. S., Field, J., Herskowitz, I., and Wigler, M. (1986) Cell 47, 413-422
4. Hrycyna, C. A., Sapperstein, S. K., Clarke, S., and Michaelis, S. (1991) EMBO J. 10, 1699-1709
5. Boyartchuk, V. L., Ashby, M. N., and Rine, J. (1997) Science 275, 1796-1800
6. Boyartchuk, V. L., and Rine, J. (1998) Genetics 150, 95-101
7. Trueblood, C. E., Boyartchuk, V. L., Picologlou, E. A., Rozema, D., Poulter, C. D., and Rine, J. (2000) Mol. Cell. Biol. 20, 4381-4392
8. Fujimura-Kamada, K., Nouvet, F. J., and Michaelis, S. (1997) J. Cell Biol. 136, 271-285
9. Tam, A., Nouvet, F. J., Fujimura-Kamada, K., Slunt, H., Sisodia, S. S., and Michaelis, S. (1998) J. Cell Biol. 142, 635-649
10. Schmidt, W. K., Tam, A., and Michaelis, S. (2000) J. Biol. Chem. 275, 6227-6233
11. Kim, E., Ambroziak, P., Otto, J. C., Taylor, B., Ashby, M., Shannon, K., Casey, P. J., and Young, S. G. (1999) J. Biol. Chem. 274, 8383-8390
12. Otto, J. C., Kim, E., Young, S. G., and Casey, P. J. (1999) J. Biol. Chem. 274, 8379-8382
13. Bergo, M. O., Leung, G. K., Ambroziak, P., Otto, J. C., Casey, P. J., Gomes, A. Q., Seabra, M. C., and Young, S. G. (2001) J. Biol. Chem. 276, 5841-5845
14. Ploger, R., Zhang, J., Bassett, D., Reeves, R., Hieter, P., Bouguski, M., and Spencer, F. (2000) Nucleic Acids Res. 28, 120-122
15. Romano, J. D., Schmidt, W. K., and Michaelis, S. (1998) Mol. Biol. Cell 9, 2231-2247
16. Michaelis, S., and Herskowitz, I. (1988) Mol. Cell. Biol. 8, 1309-1318
17. Sherman, F. (1991) Methods Enzymol. 194, 3-21
18. Gietz, R. D., and Sugino, A. (1988) Gene (Amst.) 74, 527-534
19. Hudson, H. R., Jr., Dawson, E. P., Rusjing, K. L., Jackson, C. H., Lockshon, D., Conover, D., Lanciault, C., Harris, J. R., Simmons, S. J., Rothstein, R., and Fields, S. (1997) Genome Res. 7, 1169-1172
20. Clarke, S., Vogel, J. P., Deschenes, R. J., and Stock, J. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 4643-4647
21. Kim, E., Lowenson, J. D., MacLaren, D. C., Clarke, S., and Young, S. G. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 6132-6137
22. Bergo, M. O., Leung, G. K., Ambroziak, P., Otto, J. C., Casey, P. J., and Young, S. G. (2000) J. Biol. Chem. 275, 17605-17610
23. Hanks, M., Wurst, W., Anson-Cartwright, L., Auerbach, A. B., and Joyner, A. L. (1995) Science 269, 679-682
24. Meiner, V. L., Cases, S., Myers, H. M., Sande, E. R., Bellosta, S., Schambelan, M., Pitas, R. E., McGuire, J., Herz, J., and Farese, R. V., Jr. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 14041-14046
25. Hasty, P., Bradley, A., Morris, J. H., Edmondson, D. G., Venuti, J. M., Olson, E. N., and Klein, W. H. (1993) Nature 364, 501-506
26. Mortensen, R. (1999) in Current Protocols in Molecular Biology (Ausubel, F. M. , Brent, R. , Kingston, R. E. , Moore, D. D. , Seidman, J. G. , Smith, J. A. , and Struhl, K., eds), Vol. 2 , pp. 9.16.1-9.16.11, John Wiley & Sons, New York
27. Nijbroek, G. L., and Michaelis, S. (1998) Methods Enzymol. 292, 193-212
28. Chan, R. K., and Otte, C. A. (1982) Mol. Cell. Biol. 2, 11-20
29. Chen, P., Sapperstein, S. K., Choi, J. D., and Michaelis, S. (1997) J. Cell Biol. 136, 251-269
30. Sapperstein, S., Berkower, C., and Michaelis, S. (1994) Mol. Cell. Biol. 14, 1438-1449
31. Hrycyna, C. A., and Clarke, S. (1992) J. Biol. Chem. 267, 10457-10464
32. Ashby, M. N. (1998) Curr. Opin. Lipidol. 9, 99-102
33. Chen, Y., Ma, Y.-T., and Rando, R. R. (1996) Biochemistry 35, 3227-3237


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
ScienceHome page
S. Ricardo and R. Lehmann
An ABC Transporter Controls Export of a Drosophila Germ Cell Attractant
Science, February 13, 2009; 323(5916): 943 - 946.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Coffinier, S. E. Hudon, R. Lee, E. A. Farber, C. Nobumori, J. H. Miner, D. A. Andres, H. P. Spielmann, C. A. Hrycyna, L. G. Fong, et al.
A Potent HIV Protease Inhibitor, Darunavir, Does Not Inhibit ZMPSTE24 or Lead to an Accumulation of Farnesyl-prelamin A in Cells
J. Biol. Chem., April 11, 2008; 283(15): 9797 - 9804.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Coffinier, S. E. Hudon, E. A. Farber, S. Y. Chang, C. A. Hrycyna, S. G. Young, and L. G. Fong
From the Cover: HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells
PNAS, August 14, 2007; 104(33): 13432 - 13437.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. L. Kilpatrick and J. D. Hildebrandt
Sequence Dependence and Differential Expression of G{gamma}5 Subunit Isoforms of the Heterotrimeric G Proteins Variably Processed after Prenylation in Mammalian Cells
J. Biol. Chem., May 11, 2007; 282(19): 14038 - 14047.
[Abstract] [Full Text] [PDF]


Home page
GENES CELLSHome page
R. Ukekawa, K. Miki, M. Fujii, H. Hirano, and D. Ayusawa
Accumulation of multiple forms of lamin A with down-regulation of FACE-1 suppresses growth in senescent human cells
Genes Cells, March 1, 2007; 12(3): 397 - 406.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. G. Young, M. Meta, S. H. Yang, and L. G. Fong
Prelamin A Farnesylation and Progeroid Syndromes
J. Biol. Chem., December 29, 2006; 281(52): 39741 - 39745.
[Abstract] [Full Text] [PDF]


Home page
Eukaryot CellHome page
G. Huyer, A. Kistler, F. J. Nouvet, C. M. George, M. L. Boyle, and S. Michaelis
Saccharomyces cerevisiae a-Factor Mutants Reveal Residues Critical for Processing, Activity, and Export.
Eukaryot. Cell, September 1, 2006; 5(9): 1560 - 1570.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
A. E. Rusinol and M. S. Sinensky
Farnesylated lamins, progeroid syndromes and farnesyl transferase inhibitors.
J. Cell Sci., August 15, 2006; 119(Pt 16): 3265 - 3272.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
S. G. Young, L. G. Fong, and S. Michaelis
Thematic Review Series: Lipid Posttranslational Modifications. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis
J. Lipid Res., December 1, 2005; 46(12): 2531 - 2558.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
A. Yamashita, R. Kamata, N. Kawagishi, H. Nakanishi, H. Suzuki, T. Sugiura, and K. Waku
Roles of C-Terminal Processing, and Involvement in Transacylation Reaction of Human Group IVC Phospholipase A2 (cPLA2{gamma})
J. Biochem., May 1, 2005; 137(5): 557 - 567.
[Abstract] [Full Text] [PDF]


Home page
Sci Aging Knowl EnvironHome page
Zmpste24-/- Mice
Sci. Aging Knowl. Environ., January 12, 2005; 2005(2): tg1 - tg1.
[Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. G. Fong, J. K. Ng, M. Meta, N. Cote, S. H. Yang, C. L. Stewart, T. Sullivan, A. Burghardt, S. Majumdar, K. Reue, et al.
Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice
PNAS, December 28, 2004; 101(52): 18111 - 18116.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
A. Muchir and H. J. Worman
The Nuclear Envelope and Human Disease
Physiology, October 1, 2004; 19(5): 309 - 314.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. O. Bergo, H. D. Lieu, B. J. Gavino, P. Ambroziak, J. C. Otto, P. J. Casey, Q. M. Walker, and S. G. Young
On the Physiological Importance of Endoproteolysis of CAAX Proteins: HEART-SPECIFIC RCE1 KNOCKOUT MICE DEVELOP A LETHAL CARDIOMYOPATHY
J. Biol. Chem., February 6, 2004; 279(6): 4729 - 4736.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. O. Bergo, B. Gavino, J. Ross, W. K. Schmidt, C. Hong, L. V. Kendall, A. Mohr, M. Meta, H. Genant, Y. Jiang, et al.
Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect
PNAS, October 1, 2002; 99(20): 13049 - 13054.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Bracha, M. Lavy, and S. Yalovsky
The Arabidopsis AtSTE24 Is a CAAX Protease with Broad Substrate Specificity
J. Biol. Chem., August 9, 2002; 277(33): 29856 - 29864.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Tam, W. K. Schmidt, and S. Michaelis
The Multispanning Membrane Protein Ste24p Catalyzes CAAX Proteolysis and NH2-terminal Processing of the Yeast a-Factor Precursor
J. Biol. Chem., December 7, 2001; 276(50): 46798 - 46806.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/31/29051    most recent
M102908200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leung, G. K.
Right arrow Articles by Young, S. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leung, G. K.
Right arrow Articles by Young, S. G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement